PTC Therapeutics, Inc. (BH3.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
As of 08:13AM CEST. Market open.
| Previous close | 23.40 |
| Open | 24.00 |
| Bid | 24.00 x N/A |
| Ask | 25.00 x N/A |
| Day's range | 24.00 - 24.00 |
| 52-week range | 16.40 - 54.50 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 1.915B |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -7.85 |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksPTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PR NewswirePTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2024 financial results and provide an update on the company's business and outlook on Thursday, April 25, at 4:30 p.m. ET.
PR NewswirePTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin MAA to the European Medicines Agency. The MAA submission is for the treatment of pediatric and adult patients with PKU, including the full spectrum of disease subtypes.
© 2024 Yahoo. All rights reserved.